News and Trends 7 Apr 2016
Allergan Signs Massive €3Bn Alzheimer’s Deal with UK Biotech
Heptares Therapeutics is licensing its portfolio of novel candidates for neurological diseases, including one for Alzheimer’s, to Allergan for up to €3Bn. A good way for Allergan to ‘get over’ yesterday’s failed Pfizer acquisition. Based in Cambridge, UK, Heptares Therapeutics is creating new therapies with their StaR platform, that allows it to target G protein-coupled receptors (GPCRs), a superfamily of 375 receptors linked to many […]